Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 60 clinical trials
Study to Assess Safety Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the …

Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 28 views
  • 07 May, 2021
  • +27 other locations
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the …

Royal Childrens Hospital Melbourne
 (3.2 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +67 other locations
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.

Alfred Health ( Site 0018)
 (6.7 away) Contact site
  • 742 views
  • 16 Jun, 2021
  • +52 other locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

Investigational Site Number 0360005
 (5.4 away) Contact site
  • 0 views
  • 14 Jun, 2021
  • +8 other locations
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma

This research is being done with the aim of developing a more effective treatment than standard radiotherapy and surgery alone. Although standard treatment is frequently successful, some patients do not respond well to this treatment. Low oxygen levels in tumours, which may be a particular problem with sarcomas, are thought …

cancer
Peter MacCallum Cancer Centre
 (5.9 away) Contact site
  • 12 views
  • 07 Nov, 2020
  • 1 location
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

The purpose of the first phase of the study is to determine whether, and at what dose, depsipeptide, bortezomib and dexamethasone can be safely administered to patients with Multiple Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients …

dexamethasone
calcium
maintenance therapy
serum calcium
growth factor
Peter MacCallum Cancer Centre
 (5.2 away) Contact site
  • 31 views
  • 07 Nov, 2020
  • 1 location
Safety and Efficacy of SX600 Administered by Lumbosacral Transforaminal Epidural Injection for Radicular Pain

This is a Phase I/II, double-blind, parallel-group, randomized, placebo-controlled multi-centre trial in 180 patients randomized 1:1:1 to receive the IMP (Dexamethasone acetate microspheres for extended-release injectable micro-suspension, SX600 at 12.5 mg or 25.0 mg) or Placebo (0.9% Sodium Chloride for Injection, BP) via transforaminal epidural injection to the lumbosacral epidural …

Research Site 01
 (5.2 away) Contact site
  • 70 views
  • 27 Jan, 2021
  • +10 other locations
Targeted Therapy and Avelumab in Merkel Cell Carcinoma

10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor radionuclide therapy; PRRT) or external beam radiation therapy (EBRT) in patients with metastatic Merkel cell carcinoma (mMCC).

Peter MacCallum Cancer Centre
 (5.4 away) Contact site
  • 0 views
  • 29 Apr, 2021
  • +5 other locations
A Study to Evaluate the Safety and Tolerability of EXN407

This first in human (FIH), Phase Ib/II study of EXN407 is a randomised, double-masked, vehicle-controlled, multiple dose, dose-escalating study to evaluate the safety and tolerability of EXN407 in subjects with centre involved Diabetic Macular Oedema (DMO), with Centre-subfield macular thickness (CMT) between 280-420 m and Best corrected visual acuity (BCVA) …

Centre for Eye Research Australia (CERA)
 (5.9 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +8 other locations
Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of …

myeloid leukemia
azacitidine
leukemia
cytarabine
aml/mds
Victoria Cancer Care Center
 (5.4 away) Contact site
  • 0 views
  • 05 Apr, 2021
  • +94 other locations